Dr. Sam on Therapeutic Developments in Metastatic HER2+ Breast Cancer


In Partnership With:

Christine Sam, MD, discusses therapeutic developments in metastatic HER2-positive breast cancer.

Christine Sam, MD, assistant member, Department of Individualized Cancer Management/ Senior Adult Oncology Program, Moffitt Cancer Center, discusses therapeutic developmentsin metastatic HER2-positive breast cancer.

The treatment paradigm of HER2-positive breast cancer has grown considerably in recent years in both the early-stage and metastatic settings, Sam explains. In the metastatic setting, where there were significant unmet needs, tucatinib (Tukysa) and fam-trastuzumab deruxtecan-nxki (Enhertu) represent welcome additions to the armamentarium, Sam adds.

Notably, tucatinib has demonstrated activity in terms of progression-free survival and overall survival benefit in patients with central nervous system (CNS) metastases. Prior to the phase 2 HER2CLIMB trial (NCT02614794) with tucatinib, clinical trials typically excluded patients with CNS involvement, Sam concludes.

Related Videos
Mike Lattanzi, MD, medical oncologist, Texas Oncology
Vikram M. Narayan, MD, assistant professor, Department of Urology, Emory University School of Medicine, Winship Cancer Institute; director, Urologic Oncology, Grady Memorial Hospital
Stephen V. Liu, MD
S. Vincent Rajkumar, MD
Pashtoon Murtaza Kasi, MD, MS
Naseema Gangat, MBBS
Samilia Obeng-Gyasi, MD, MPH,
Kian-Huat Lim, MD, PhD
Saurabh Dahiya, MD, FACP, associate professor, medicine (blood and marrow transplantation and cellular therapy), Stanford University School of Medicine, clinical director, Cancer Cell Therapy, Stanford BMT and Cell Therapy Division
Muhamed Baljevic, MD